Cambrex Acquires Snapdragon Chemistry

Noramco Acquires Cambrex Drug Product Business Unit (Halo Pharmaceuticals)

November 2, 2023

Pharmaceuticals

Noramco has completed the acquisition of the Cambrex Drug Product Business Unit (previously Halo Pharmaceuticals), adding drug product formulation development, clinical and commercial manufacturing, and packaging capabilities from sites in Mirabel, Québec and Whippany, New Jersey. The purchase expands Noramco's service offering beyond APIs, brings nearly 400 employees into the Noramco group, and represents Cambrex's strategic divestiture to focus on its drug substance and analytical testing businesses.

Aceto Acquires Cascade Chemistry

June 2, 2021

Pharmaceuticals

Aceto, a global provider of specialty materials for life sciences and advanced technology end markets, acquired Eugene, Oregon-based Cascade Chemistry, a CDMO specializing in active pharmaceutical ingredients (APIs) and advanced intermediates. The acquisition strengthens Aceto's U.S. cGMP custom manufacturing capabilities and expands North American API manufacturing capacity; Cascade Chemistry recently announced a facility expansion that will triple its clinical-stage API capacity.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.

Snapdragon Capital Partners & The Maze Group Acquire Minority Stake in Nutraceutical International

July 17, 2019

Consumer Products

HGGC sold a minority stake in Nutraceutical International Corporation to Snapdragon Capital Partners and The Maze Group, with a DWS-led investor group providing support. The investment is intended to accelerate Nutraceutical’s digital transformation and omnichannel growth while HGGC remains a significant partner; terms were not disclosed.

Novacap Acquires PCI Synthesis

June 28, 2018

Pharmaceuticals

Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.

CPS Fluidics Acquires Hexano Corp

December 13, 2022

Medical Devices

CPS Fluidics, a Wallingford, Connecticut-based contract manufacturer focused on microfluidics for the life sciences, has acquired Hexano Corp, a microfluidic cartridge manufacturer founded in 2018. The acquisition brings Hexano founder Andre Babineau into CPS Fluidics as VP of Sales and is intended to expand CPS Fluidics' manufacturing, prototyping capabilities and domestic and international market reach.